Pegfilgrastim-pbbk - Biologic Drug Details

Summary for pegfilgrastim-pbbk

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for pegfilgrastim-pbbk

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pegfilgrastim-pbbk Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pegfilgrastim-pbbk Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pegfilgrastim-pbbk Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pegfilgrastim-pbbk

Last updated: March 17, 2026

What Is Pegfilgrastim-pbbk?

Pegfilgrastim-pbbk is a biosimilar competitor to Neulasta (pegfilgrastim), a long-acting granulocyte colony-stimulating factor (G-CSF). Approved by the FDA in May 2023, it targets the prevention of febrile neutropenia in chemotherapy patients.

Market Landscape Overview

Key Players and Approvals

Product	Manufacturer	Approval Date	Indications	Market Status
Neulasta	Amgen	2002	Chemotherapy-induced neutropenia	Market leader
Pegfilgrastim-pbbk		2023	Same as Neulasta	First biosimilar approval from a major competitor

Biosimilar Entry Impact

The FDA approval of pegfilgrastim-pbbk marks the first biosimilar to pegfilgrastim, challenging a market valued at approximately $4 billion in the U.S. (IQVIA, 2023). It introduces price competition and prompts shift in prescribing patterns.

Pricing Dynamics

Approach	Details
List Price	Approximately 15-25% lower than Neulasta
Reimbursement	Similar to originator; insurance coverage expected to favor generics
Discounting	Manufacturers may offer rebates to secure formulary inclusion

Competitive Pressure

The entry is expected to reduce Neulasta's average selling price (ASP) by 10-15% in the next two years. It may also influence prescribing trends, with some oncologists favoring biosimilars for their cost benefits.

Market Adoption Factors

Regulatory Approvals and Pathways

• The FDA approval process for pegfilgrastim-pbbk follows the Biosimilar User Fee Act (BsUFA) guidelines, requiring demonstration of biosimilarity, pharmacokinetic/pharmacodynamic equivalence, and safety profile.

Physician and Hospital Adoption

• Prescriber acceptance hinges on perceived efficacy, safety, and educational outreach.
• Hospitals aim for cost savings through biosimilars to reduce chemotherapy-related treatment expenses.

Patent Litigation and Market Entry Barriers

• Certain patents on Neulasta extend into 2024, delaying biosimilar market penetrations.
• Biosimilar approval lowers market entry barriers over time.

Financial Trajectory

Revenue Projections

Timeframe	Estimated Market Share	Revenue (USD millions)	Notes
Year 1 (2023)	5-8%	$200-$300	Initial uptake, cautious prescriber adoption
Year 2 (2024)	15-20%	$600-$1,200	Growing formulary inclusion, pricing effects
Year 3 (2025)	25-30%	$1,200-$2,200	Mainstream adoption in oncology settings

Key Revenue Drivers

• Price competition reduces costs
• Expanded reimbursement coverage
• Increased awareness and physician confidence

Challenges

• Slow physician prescribing adoption
• Patent litigation delays
• Limited manufacturing capacity initially

Regional Market Considerations

Region	Trends	Approval Status	Market Size (USD millions)
United States	Rapid adoption expected	FDA approved	$4,000 (2023)
European Union	Pending EMA approval	Under review	$2,000 (estimated)
Asia-Pacific	Growing oncology market	Early-stage approval	$1,000 (estimated)

Strategic Implications

• Early entry provides competitive advantage.
• Focus on formulary negotiations and physician education.
• Patent landscapes should be monitored to prevent infringement risks.

Summary

Pegfilgrastim-pbbk's FDA approval introduces a significant competitor to Neulasta, likely leading to price reductions and increased market penetration. Its financial success depends on supplier capacity, regulatory strategies, and market acceptance. Adoption may accelerate as biosimilar pricing pressures intensify and prescriber familiarity increases.

---

Key Takeaways

• Pegfilgrastim-pbbk entered the US market in 2023, impacting a $4 billion segment.
• Market adoption will depend on pricing, physician acceptance, and patent litigation.
• Revenue growth could reach approximately $2.2 billion by 2025 with a 25-30% market share.
• Competitive dynamics will influence originator pricing and reimbursement strategies.
• Regional expansion hinges on regulatory approvals and local market factors.

---

FAQs

1. What is the significance of pegfilgrastim biosimilars in oncology?
They provide less expensive alternatives, increasing access and reducing treatment costs.

2. How does biosimilar approval differ from generic drug approval?
Biosimilar approval requires demonstrating similarity in structure, function, safety, and efficacy, not identical chemical composition.

3. What are the main barriers for biosimilar market penetration?
Patent protections, physician acceptance, manufacturing capacity, and payer formulary restrictions.

4. How do biosimilar pricing strategies influence the overall market?
Lower list prices and rebates foster formulary placement, leading to broader adoption and cost savings.

5. What is the potential for international expansion of pegfilgrastim-pbbk?
Based on regional regulatory status, market size, and local pricing, expansion can complement US growth, notably in Europe and Asia.

---

References

1. IQVIA. (2023). US Oncology Market Data. IQVIA Institute.
2. U.S. Food and Drug Administration. (2023). Approval of Pegfilgrastim-pbbk. FDA.gov.